Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 224Rectal Neoplasms 124Colonic Neoplasms 120Stomach Neoplasms 60Pancreatic Neoplasms 58Neoplasm Metastasis 48Lymphoma 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Leukemia 32Esophageal Neoplasms 32Neoplasms 31Burkitt Lymphoma 19Adenocarcinoma Of Esophagus 17Adenocarcinoma 17Carcinoma, Hepatocellular 13Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Unspecified Adult Solid Tumor, Protocol Specific 11Biliary Tract Neoplasms 11Lymphoma, Mantle-Cell 10Gallbladder Neoplasms 10Liver Neoplasms 9Osteosarcoma 8Lymphoma, Large-Cell, Immunoblastic 8Gastrointestinal Neoplasms 8Bile Duct Neoplasms 8Lymphoma, Follicular 7Dendritic Cell Sarcoma, Interdigitating 7Cholangiocarcinoma 7Leukemia, Myeloid, Acute 6

Interventions

napabucasin 3Irinotecan 3Gemcitabine 3Bevacizumab 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3entinostat 2Paclitaxel 2Leucovorin 2Fluorouracil 2sipuleucel-T 1pralsetinib 1pembrolizumab 1luprolide acetate gel depot 1lenvatinib 1interferon gamma-1b 1ficlatuzumab 1catumaxomab 1Vaccines 1Papillomavirus Vaccines 1Oncolytic Virotherapy 1Ocoxin 1Nivolumab 1Leuprolide 1Interferon-gamma 1Immunotherapy 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Gefitinib 1Filgrastim 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasms, Glandular and Epithelial × Leucovorin × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡